Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants?: Figure 1.

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer

(2015) M. Nakazawa et al.   ANNALS OF ONCOLOGY

Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

(2015) Nicholas David James et al.   EUROPEAN UROLOGY

Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study

(2015) M. T. Schweizer et al.   Science Translational Medicine

Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer

(2014) Maria Thadani-Mulero et al.   CANCER RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

(2014) Emmanuel S. Antonarakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer

(2014) Cynthia C. T. Sprenger et al.   Hormones & Cancer

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

(2010) Alison H.M. Reid et al.   JOURNAL OF CLINICAL ONCOLOGY